iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/32342999
Akathisia and Newer Second-Generation Antipsychotic Drugs: A Review of Current Evidence - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;40(6):565-574.
doi: 10.1002/phar.2404. Epub 2020 May 20.

Akathisia and Newer Second-Generation Antipsychotic Drugs: A Review of Current Evidence

Constance L Chow  1 , Nour K Kadouh  2 , Jolene R Bostwick  2 , Amy M VandenBerg  3
Affiliations
Free article
Review

Akathisia and Newer Second-Generation Antipsychotic Drugs: A Review of Current Evidence

Constance L Chow et al. Pharmacotherapy. 2020 Jun.
Free article

Abstract

Akathisia continues to present a significant challenge in clinical practice. As a class, so-called atypical, or second-generation, antipsychotics (SGAs) are the mainstay of treatment for schizophrenia and are commonly used to treat mood disorders. These medications have traditionally been distinguished from first-generation antipsychotics by their lowered risk of extrapyramidal side effects (EPS) such as dystonia, dyskinesia, akathisia, and pseudoparkinsonism. However, the occurrence of EPS, particularly akathisia, has been demonstrated to some degree in all commercially available SGAs. This review examines the incidence of akathisia in nine newer SGAs in patients with schizophrenia, bipolar disorder, and major depressive disorder (MDD). We performed a search of PubMed, ClinicalTrials.gov, Cochrane Central Register, and Google Scholar, as well as manufacturer websites and product labeling for published and unpublished clinical trials, meta-analyses, and systematic reviews. Studies evaluating adult patients with schizophrenia, bipolar disorder, or MDD were eligible for inclusion. Data on treatment-emergent akathisia rates were gathered from each study, and potential dose-response relationships were explored. A total of 177 studies were included in this review, comprising 58,069 patients across 414 treatment arms. Compared with placebo with a composite 3.7% incidence of akathisia, individual SGAs produced akathisia at total composite rates ranging from 2.9-13.0% across the included studies. High doses of an SGA were generally associated with an increased risk of akathisia. Clinicians should consider the risk of akathisia when choosing a treatment option and monitor for akathisia in patients beginning therapy with an SGA or following a dose increase of the SGA.

Keywords: akathisia; antipsychotics; bipolar disorder; major depressive disorder; schizophrenia.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull 2003;29(3):547-58.
    1. Barnes TRE. The Barnes Akathisia rating scale-revisited. J Psychopharmacol (Oxf) 2003;17(4):365-70.
    1. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, Assunção-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70(5):627-43.
    1. Putten TV. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31(1):67-72.
    1. Seemüller F, Lewitzka U, Bauer M, et al. The relationship of akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry 2012;45(07):292-6.

MeSH terms

Substances